JP2004075689A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004075689A5 JP2004075689A5 JP2003311358A JP2003311358A JP2004075689A5 JP 2004075689 A5 JP2004075689 A5 JP 2004075689A5 JP 2003311358 A JP2003311358 A JP 2003311358A JP 2003311358 A JP2003311358 A JP 2003311358A JP 2004075689 A5 JP2004075689 A5 JP 2004075689A5
- Authority
- JP
- Japan
- Prior art keywords
- methylerythromycin
- powder
- ray diffraction
- solvate
- substantially free
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical group O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 111
- 238000000634 powder X-ray diffraction Methods 0.000 claims 27
- 239000012453 solvate Substances 0.000 claims 24
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims 23
- 229940011051 isopropyl acetate Drugs 0.000 claims 23
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims 22
- 238000002360 preparation method Methods 0.000 claims 20
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 claims 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 10
- YBZRLMLGUBIIDN-UHFFFAOYSA-N Spicamycin Chemical compound O1C(C(O)CO)C(NC(=O)CNC(=O)CCCCCCCCCCCCC(C)C)C(O)C(O)C1NC1=NC=NC2=C1NC=N2 YBZRLMLGUBIIDN-UHFFFAOYSA-N 0.000 claims 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 7
- MWBJRTBANFUBOX-SQYJNGITSA-N (3r,4s,5s,6r,7r,9r,10e,11s,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-10-hydroxyimino-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclot Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/O)/[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MWBJRTBANFUBOX-SQYJNGITSA-N 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical group O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 5
- 229920002125 Sokalan® Polymers 0.000 claims 5
- 229960001631 carbomer Drugs 0.000 claims 5
- 239000002904 solvent Substances 0.000 claims 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 3
- 229960002626 clarithromycin Drugs 0.000 claims 3
- 229960003276 erythromycin Drugs 0.000 claims 3
- KYTWXIARANQMCA-RWJQBGPGSA-N (3r,4s,5s,6r,7r,9r,11s,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-10-hydroxyimino-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2 Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=NO)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 KYTWXIARANQMCA-RWJQBGPGSA-N 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 229930006677 Erythromycin A Natural products 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000047 product Substances 0.000 claims 2
- OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical compound CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 claims 2
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000003701 inert diluent Substances 0.000 claims 1
- 239000012022 methylating agents Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/785,623 US5945405A (en) | 1997-01-17 | 1997-01-17 | Crystal form O of clarithromycin |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53437298A Division JP4058114B2 (ja) | 1997-01-17 | 1997-12-19 | クラリスロマイシンの結晶形態０ |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008327022A Division JP5190350B2 (ja) | 1997-01-17 | 2008-12-24 | クラリスロマイシンの結晶形態０ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004075689A JP2004075689A (ja) | 2004-03-11 |
| JP2004075689A5 true JP2004075689A5 (https=) | 2005-10-27 |
Family
ID=25136084
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53437298A Expired - Lifetime JP4058114B2 (ja) | 1997-01-17 | 1997-12-19 | クラリスロマイシンの結晶形態０ |
| JP2003311358A Withdrawn JP2004075689A (ja) | 1997-01-17 | 2003-09-03 | クラリスロマイシンの結晶形態０ |
| JP2008327022A Expired - Lifetime JP5190350B2 (ja) | 1997-01-17 | 2008-12-24 | クラリスロマイシンの結晶形態０ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53437298A Expired - Lifetime JP4058114B2 (ja) | 1997-01-17 | 1997-12-19 | クラリスロマイシンの結晶形態０ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008327022A Expired - Lifetime JP5190350B2 (ja) | 1997-01-17 | 2008-12-24 | クラリスロマイシンの結晶形態０ |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5945405A (https=) |
| EP (1) | EP1077988A1 (https=) |
| JP (3) | JP4058114B2 (https=) |
| KR (1) | KR100567149B1 (https=) |
| CN (1) | CN1174991C (https=) |
| AR (3) | AR011077A1 (https=) |
| AU (1) | AU735598B2 (https=) |
| BR (1) | BR9714287A (https=) |
| CA (4) | CA2277274C (https=) |
| CZ (1) | CZ297433B6 (https=) |
| DE (1) | DE97951771T1 (https=) |
| ES (1) | ES2173058T1 (https=) |
| IL (1) | IL130255A0 (https=) |
| NZ (1) | NZ336073A (https=) |
| TR (1) | TR199901578T2 (https=) |
| TW (1) | TW574224B (https=) |
| WO (1) | WO1998031699A1 (https=) |
| ZA (1) | ZA98116B (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5945405A (en) * | 1997-01-17 | 1999-08-31 | Abbott Laboratories | Crystal form O of clarithromycin |
| KR100377159B1 (ko) * | 1998-09-09 | 2003-08-19 | 한미약품공업 주식회사 | 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법 |
| GB9827355D0 (en) * | 1998-12-11 | 1999-02-03 | Biochemie Sa | Organic compounds |
| KR100322313B1 (ko) * | 1999-10-21 | 2002-02-06 | 민경윤 | 클라리스로마이신 결정형 2의 제조방법 및 이에 사용되는 클라리스로마이신 포르메이트 |
| US6627743B1 (en) | 1999-12-03 | 2003-09-30 | Abbott Laboratories | 6-O-methylerythromycin A crystal form III |
| WO2001044262A1 (en) * | 1999-12-16 | 2001-06-21 | Teva Pharmaceutical Industries Ltd. | Processes for preparing clarithromycin polymorphs and novel polymorph iv |
| FR2802534B1 (fr) * | 1999-12-20 | 2002-02-01 | Merial Sas | Procede pour preparer et isoler la 9-deoxo-9 (z)- hydroxyiminoerythromycine a |
| AU2261901A (en) | 2000-01-11 | 2001-07-24 | Teva Pharma | Processes for preparing clarithromycin polymorphs |
| US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
| US6565882B2 (en) | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
| KR20030047873A (ko) * | 2000-02-29 | 2003-06-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | 클라리트로마이신 및 클라리트로마이신 중간체의 제조방법, 실질적으로는 옥심이 제거된 클라리트로마이신 및이를 포함하는 약학적 조성물 |
| RU2230748C2 (ru) * | 2000-03-15 | 2004-06-20 | Ханми Фарм. Ко., Лтд. | Способ получения кларитромицина в виде кристаллов формы ii |
| KR100367981B1 (ko) * | 2000-11-23 | 2003-01-14 | 한미약품공업 주식회사 | 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물 |
| AU2001263812B2 (en) * | 2000-03-28 | 2004-09-23 | Sandoz Ag | Granulated particles with masked taste |
| US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
| US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| ATE485837T1 (de) * | 2000-08-03 | 2010-11-15 | Antares Pharma Ipl Ag | Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert |
| US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| US6541014B2 (en) | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
| US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
| KR100408848B1 (ko) * | 2001-03-12 | 2003-12-06 | 주식회사 씨트리 | 클래리스로마이신의 정제방법 |
| RU2217160C2 (ru) * | 2001-04-20 | 2003-11-27 | Челябинская государственная медицинская академия | Способ местного лечения урогенитального хламидиоза у женщин |
| ES2323264T3 (es) * | 2001-08-01 | 2009-07-10 | Novartis Ag | Composicion para enmascaramiento del sabor. |
| TW200302830A (en) * | 2002-01-11 | 2003-08-16 | Chugai Pharmaceutical Co Ltd | Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate |
| CN100427498C (zh) * | 2003-03-02 | 2008-10-22 | 王凌峰 | 克拉霉素a型结晶 |
| US20040185092A1 (en) * | 2003-03-18 | 2004-09-23 | Yih Ming Hsiao | Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use |
| AU2004258953B2 (en) | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| JP2006528185A (ja) | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
| AU2004258949B2 (en) | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| CA2535177A1 (en) | 2003-08-11 | 2005-02-24 | Advancis Pharmaceutical Corporation | Robust pellet |
| US8062672B2 (en) | 2003-08-12 | 2011-11-22 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
| AU2004270170B2 (en) * | 2003-08-29 | 2011-01-27 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| CA2538064C (en) | 2003-09-15 | 2013-12-17 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
| ATE534373T1 (de) | 2003-10-10 | 2011-12-15 | Antares Pharma Ipl Ag | Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut |
| CA2572292A1 (en) | 2004-07-02 | 2006-02-09 | Advancis Pharmaceutical Corporation | Tablet for pulsed delivery |
| US20060111560A1 (en) * | 2004-11-01 | 2006-05-25 | Glenmark Pharmaceuticals Limited | Process for the preparation of crystalline form II of clarithromycin |
| US8067399B2 (en) | 2005-05-27 | 2011-11-29 | Antares Pharma Ipl Ag | Method and apparatus for transdermal or transmucosal application of testosterone |
| JP2009500356A (ja) * | 2005-07-07 | 2009-01-08 | エラン ファーマ インターナショナル リミテッド | ナノ粒子クラリスロマイシン製剤 |
| WO2007036951A2 (en) * | 2005-08-31 | 2007-04-05 | Alembic Limited | Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii |
| US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
| US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
| CN101426475A (zh) * | 2006-04-21 | 2009-05-06 | 安塔雷斯制药Ipl股份公司 | 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法 |
| US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
| WO2008067991A2 (en) * | 2006-12-08 | 2008-06-12 | Antares Pharma Ipl Ag | Skin-friendly drug complexes for transdermal administration |
| DE102007016367A1 (de) | 2007-04-03 | 2008-10-09 | Grünenthal GmbH | Polymorph von Clarithromycin (Form V) |
| US20090054634A1 (en) * | 2007-08-09 | 2009-02-26 | Vinod Kumar Kansal | Process for the preparation of clarithromycin |
| EP2030613A1 (en) | 2007-08-17 | 2009-03-04 | Abbott GmbH & Co. KG | Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics |
| US9119769B2 (en) | 2011-12-30 | 2015-09-01 | The Curators Of The University Of Missouri | Method for transforming pharmaceutical crystal forms |
| CN103087130B (zh) * | 2013-02-06 | 2015-12-23 | 浙江国邦药业有限公司 | 一种克拉霉素晶型转换方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5782400A (en) | 1980-11-12 | 1982-05-22 | Taisho Pharmaceut Co Ltd | Erythromycin derivative |
| US4331803A (en) * | 1980-06-04 | 1982-05-25 | Taisho Pharmaceutical Co., Ltd. | Novel erythromycin compounds |
| JPS60214796A (ja) * | 1984-04-06 | 1985-10-28 | Taisho Pharmaceut Co Ltd | ６−０−メチルエリスロマイシン類の製法 |
| JPS61103890A (ja) | 1984-10-26 | 1986-05-22 | Taisho Pharmaceut Co Ltd | ６−０−メチルエリスロマイシンａ誘導体 |
| US4670549A (en) * | 1985-03-18 | 1987-06-02 | Taisho Pharmaceutical Co., Ltd. | Method for selective methylation of erythromycin a derivatives |
| EP0260938B1 (en) * | 1986-09-18 | 1992-12-09 | Taisho Pharmaceutical Co. Ltd | Erythromycin a derivatives and method for preparing the same |
| JPH0755958B2 (ja) * | 1986-10-03 | 1995-06-14 | 大正製薬株式会社 | エリスロマイシンａ誘導体の製造方法 |
| KR960000434B1 (ko) * | 1986-12-17 | 1996-01-06 | 다이쇼 세이야꾸 가부시끼가이샤 | 에리스로마이신 a유도체 및 그의 제조 방법 |
| JP2526951B2 (ja) * | 1986-12-17 | 1996-08-21 | 大正製薬株式会社 | エリスロマイシンａ誘導体およびその製造方法 |
| US4808411A (en) * | 1987-06-05 | 1989-02-28 | Abbott Laboratories | Antibiotic-polymer compositions |
| JP2751385B2 (ja) * | 1988-05-19 | 1998-05-18 | 大正製薬株式会社 | エリスロマイシンａオキシム及びその塩の製造方法 |
| US5556839A (en) * | 1991-04-29 | 1996-09-17 | Eli Lilly And Company | Form II Dirithromycin |
| US5872229A (en) | 1995-11-21 | 1999-02-16 | Abbott Laboratories | Process for 6-O-alkylation of erythromycin derivatives |
| US5719272A (en) | 1996-04-02 | 1998-02-17 | Abbott Laboratories | 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives |
| US5837829A (en) | 1996-04-02 | 1998-11-17 | Abbott Laboratories | 9-oximesilyl erythromycin a derivatives |
| DE69730138T2 (de) * | 1996-07-29 | 2005-03-03 | Abbott Laboratories, Abbott Park | Herstellung von kristallinen form ii von clarithromycin |
| US5858986A (en) * | 1996-07-29 | 1999-01-12 | Abbott Laboratories | Crystal form I of clarithromycin |
| US5945405A (en) * | 1997-01-17 | 1999-08-31 | Abbott Laboratories | Crystal form O of clarithromycin |
-
1997
- 1997-01-17 US US08/785,623 patent/US5945405A/en not_active Expired - Lifetime
- 1997-12-19 ES ES97951771T patent/ES2173058T1/es active Pending
- 1997-12-19 NZ NZ336073A patent/NZ336073A/xx not_active IP Right Cessation
- 1997-12-19 CA CA002277274A patent/CA2277274C/en not_active Expired - Lifetime
- 1997-12-19 BR BR9714287-5A patent/BR9714287A/pt not_active Application Discontinuation
- 1997-12-19 KR KR1019997006446A patent/KR100567149B1/ko not_active Expired - Fee Related
- 1997-12-19 JP JP53437298A patent/JP4058114B2/ja not_active Expired - Lifetime
- 1997-12-19 CA CA002387356A patent/CA2387356C/en not_active Expired - Lifetime
- 1997-12-19 CA CA002419499A patent/CA2419499A1/en not_active Abandoned
- 1997-12-19 CZ CZ0242699A patent/CZ297433B6/cs not_active IP Right Cessation
- 1997-12-19 CA CA002387361A patent/CA2387361C/en not_active Expired - Lifetime
- 1997-12-19 IL IL13025597A patent/IL130255A0/xx not_active IP Right Cessation
- 1997-12-19 TR TR1999/01578T patent/TR199901578T2/xx unknown
- 1997-12-19 DE DE0001077988T patent/DE97951771T1/de active Pending
- 1997-12-19 WO PCT/US1997/023607 patent/WO1998031699A1/en not_active Ceased
- 1997-12-19 CN CNB971814325A patent/CN1174991C/zh not_active Expired - Fee Related
- 1997-12-19 AU AU55326/98A patent/AU735598B2/en not_active Expired
- 1997-12-19 EP EP97951771A patent/EP1077988A1/en not_active Withdrawn
- 1997-12-30 TW TW86119997A patent/TW574224B/zh not_active IP Right Cessation
-
1998
- 1998-01-07 ZA ZA98116A patent/ZA98116B/xx unknown
- 1998-01-16 AR ARP980100207A patent/AR011077A1/es not_active Application Discontinuation
-
2003
- 2003-04-24 AR ARP030101427A patent/AR039666A2/es not_active Application Discontinuation
- 2003-04-24 AR ARP030101428A patent/AR039667A2/es not_active Application Discontinuation
- 2003-09-03 JP JP2003311358A patent/JP2004075689A/ja not_active Withdrawn
-
2008
- 2008-12-24 JP JP2008327022A patent/JP5190350B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004075689A5 (https=) | ||
| JP2009137975A5 (https=) | ||
| CN100413879C (zh) | 4″-取代-9-脱氧-9a-氮杂-9a-高红霉素A衍生物的制备方法 | |
| JP5190350B2 (ja) | クラリスロマイシンの結晶形態０ | |
| CN1216892C (zh) | 甲红霉素的晶形i | |
| Bright et al. | Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides | |
| TW472060B (en) | 4""-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives | |
| JP4589110B2 (ja) | 抗炎症性活性を有するマクロライド化合物 | |
| TW200418871A (en) | C-4"-substituted macrolide derivatives | |
| HUP0204091A2 (hu) | Eljárások a clarithromycin polimorf módosulatainak előállítására és az új polimorf IV módosulat, és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| CN1133291A (zh) | 新的红霉素衍生物及其制备方法和药物用途 | |
| JP2002502366A (ja) | ３―デスクラジノース―２，３―無水エリスロマイシン誘導体 | |
| WO2007010555A2 (en) | Novel crystalline forms of moxifloxacin hydrochloride and process for preparation thereof | |
| JP2004528336A (ja) | アジスロマイシン水和物の１，２−プロピレングリコール包接化合物、その製造方法およびそれを含む医薬組成物 | |
| WO2007013086A1 (en) | Novel polymorphs of tenofovir disoproxil fumarate | |
| KR20060015750A (ko) | 지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법 | |
| CN1351607A (zh) | 大环内酯抗生素的新晶形 | |
| CN1238364C (zh) | 红霉素衍生物,其制备方法及其作为药物的用途 | |
| JP2003501439A5 (https=) | ||
| ES2254389T3 (es) | Agentes anti-infecciosos utiles contra cepas bacterianas resistntes a multiples farmacos. | |
| CN1798755A (zh) | O－烷基大环内酯和氮杂内酯衍生物和制备这些化合物的区域选择性方法 | |
| KR100467707B1 (ko) | 클래리트로마이신의 제 ２결정형의 제조 방법 | |
| US6667338B2 (en) | 9-amino erythromycin derivatives with antibacterial activity | |
| US20020132782A1 (en) | 9-amino erythromycin derivatives with antibacterial activity | |
| WO2005061524A2 (en) | Process for the preparation of form ii clarithromycin |